Kura Oncology, Inc. (KURA)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 20.8M | 17.3M | 18.3M | 20.9M |
| Gross Profit | 18.0M | 20.6M | ||
| Operating Income | (80.0M) | (86.3M) | (78.8M) | (73.0M) |
| Net Income | (74.1M) | (81.0M) | (73.3M) | (68.3M) |
| Diluted EPS | $-0.85 | $-0.92 | $-0.83 | $-0.77 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 53.9M | 67.5M |
| Gross Profit | 0.00 | 53.9M | 67.4M | |
| Operating Income | (139.9M) | (165.8M) | (193.2M) | (303.6M) |
| Net Income | (135.8M) | (152.6M) | (174.0M) | (278.7M) |
| Diluted EPS | $-2.03 | $-2.08 | $-2.02 | $-3.18 |